obesity drugs

President Donald Trump’s latest agreement with pharmaceutical giants Eli Lilly and Novo Nordisk could dramatically reshape the cost landscape for obesity treatments in the United States. The deal, announced from the Oval Office, sets a sliding scale of prices that varies by dosage, specific product, and the way a patient pays—whether through...

President Donald Trump unveiled a sweeping agreement with pharmaceutical giants Eli Lilly and Novo Nordisk that will dramatically cut the cost of their best‑selling weight‑loss medications for millions of Americans. Announced at a White House event, the deals are designed to make the drugs more affordable for patients covered by Medicare and...